The association of maternal thyroid autoimmunity during pregnancy with child IQ by Derakhshan, Arash et al.
1	
	
The Association of Maternal Thyroid Autoimmunity During Pregnancy with Child IQ 1	
Arash Derakhshan1, Tim I.M. Korevaar1 , Peter N. Taylor2, Deborah Levie1,3, Monica Guxens 3, Scott 2	
M. Nelson4, Henning Tiemeier5, Vincent W.V. Jaddoe6, Robin P. Peeters1  3	
1 Academic Centre for Thyroid Disease, Erasmus Medical Centre, Rotterdam, The Netherlands. 4	
2 Thyroid	Research	Group,	Systems Immunity Research Institute,	Cardiff	University	School	of	5	
Medicine,	Cardiff,	UK	6	
3 ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain. 7	
4 School of Medicine, University of Glasgow, Glasgow, United Kingdom. 8	
5 Department of Child and Adolescent Psychiatry, Erasmus Medical Center, Rotterdam, The 9	
Netherlands. 10	
6 The Generation R Study Group, Erasmus Medical Center, Rotterdam, The Netherlands. 11	
Short title: Thyroid Autoimmunity During Pregnancy and Child IQ 12	
Key words: Thyroperoxidase antibody; pregnancy; child; IQ 13	
Corresponding author and contact information: 14	
Tim I.M. Korevaar 15	
 16	
E-mail: t.korevaar@erasmusmc.nl 17	
Funding: 18	
Disclosure: The authors have nothing to disclose. 19	
  20	
2	
	
Abstract 21	
Context: During the first 18-20 weeks of pregnancy, the fetus depends on the placental transfer of 22	
maternal thyroid hormones, particularly for its brain development. During this time, high 23	
concentrations of human chorionic gonadotropin (hCG) stimulate the thyroid to ensure adequate 24	
thyroid hormone availability. Thyroperoxidase antibody (TPOAb) positivity, which is a major risk 25	
factor for gestational thyroid dysfunction, is associated with adverse pregnancy outcomes. We have 26	
recently shown that TPOAb positive women have an impaired thyroidal response to hCG stimulation. 27	
Objective: To study the association of maternal TPOAb positivity during pregnancy with child IQ. 28	
Design, Setting, Participants: This study was embedded in two prospective birth cohorts: Generation 29	
R (Rotterdam, the Netherlands) and the Avon Longitudinal Study of Parents and Children (ALSPAC; 30	
Avon, United Kingdom). Mother-child pairs with available data on TPOAbs in early pregnancy (≤18 31	
weeks of gestation) and offspring IQ were included (N=3637, Generation R and N=2396, ALSPAC).  32	
Intervention: None. 33	
Main Outcome Measures: Child IQ at 5 to 10 years of age. 34	
Results: In Generation R, TPOAb positivity was associated with a 2.0 ±0.9 point lower mean child IQ 35	
(P=0.03). Sensitivity analyses showed negative effect estimates already from TPOAb concentrations 36	
considerably lower than currently used manufacturer cut-offs. In ALSPAC, neither TPOAb positivity 37	
nor TPOAb concentrations below manufacturer cut-offs were associated with child IQ (TPOAb 38	
positivity: 0.7 ±1.0, P=0.45). Adjustment for maternal TSH or FT4 concentrations or urinary 39	
iodine/creatinine ratio did not change the results. 40	
Conclusion: TPOAb positivity during pregnancy was associated with lower child IQ in Generation R 41	
but not in ALSPAC. Further studies are needed to elucidate if differences between the study 42	
populations, in particular maternal iodine status, could be the underlying cause for these differences. 43	
44	
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Précis 45	
We investigated the association of TPO antibody positivity during early pregnancy with child IQ and 46	
demonstrate that TPO antibody positive mothers have children with lower IQ in one of the two 47	
studied cohorts.  48	
 49	
Introduction 50	
Thyroperoxidase antibody (TPOAb) positivity occurs in about 5.6-22.1% of all pregnant women 51	
worldwide and its prevalence differs according to maternal iodine intake, ethnicity, parity and 52	
smoking (1-4). TPOAb positivity reflects thyroid autoimmunity, which typically results in higher 53	
serum thyroid stimulating hormone (TSH) concentrations, lower serum free thyroxine (FT4) 54	
concentrations and ultimately hypothyroidism (5,6). Human chorionic gonadotropin (hCG) is a 55	
pregnancy-specific hormone that exerts thyrotropic activity via its weak affinity for the TSH receptor 56	
(7,8). During pregnancy, high hCG concentrations lead to an increase in FT4 concentrations by up to 57	
50% (9). This increase in thyroid hormone availability safeguards sufficient thyroxine transfer to the 58	
developing fetus (7). We recently showed that TPOAb positivity severely impairs the thyroidal 59	
response to hCG stimulation, and this  could affect early fetal development (10). 60	
The fetal thyroid gland is not functionally mature until the 18th to 20th week of pregnancy; therefore, 61	
fetal thyroid hormone availability during early development largely depends on the placental transfer 62	
of maternal thyroid hormones (7,11). In humans, neurogenesis starts from approximately the 5th week 63	
of pregnancy and thyroid hormone receptors are detected in the fetal brain from the 8th week of 64	
pregnancy (11). Various critical processes of fetal brain development that reach peak activity before 65	
the 18th to 20th week of pregnancy are regulated by thyroid hormone (12,13). Interestingly, the 66	
specific period during which early brain development is dependent on maternal thyroid hormone 67	
overlaps with the timeframe during which high hCG concentrations increase maternal thyroid 68	
hormone concentrations (roughly 6-15 weeks of pregnancy) (14,15). 69	
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The current guidelines of the American Thyroid Association (ATA) state that for TPOAb positive 70	
women, levothyroxine treatment can be considered when TSH concentrations are above 2.5 mU/l (4). 71	
This recommendation is predominantly based on studies showing that TPOAb positivity is associated 72	
with a higher risk of miscarriage and premature delivery (16-21). Although some studies show that 73	
low maternal thyroid function is associated with suboptimal child neurodevelopmental outcomes, 74	
such as lower IQ, autism and schizophrenia (22-26), studies on the association of maternal TPOAb 75	
positivity with child neurodevelopment remain sparse. Some studies indicate that maternal TPOAb 76	
positivity is associated with lower child IQ and a higher risk of autism or problem behavior (27-32); 77	
however, the majority of these studies were either retrospective, had a small sample size, were unable 78	
to adjust for potential confounders and/or did not investigate the combination of TPOAb positivity 79	
with a TSH concentration above 2.5 mU/l. 80	
Considering that an attenuated thyroidal response to hCG stimulation in TPOAb positive women 81	
likely leads to a relative form of thyroid hormone shortage during early pregnancy, when fetal brain 82	
development depends on maternal thyroid hormone, we hypothesized that TPOAb positivity is 83	
associated with lower child IQ. Therefore, the main aim of the current study was to investigate the 84	
association of maternal TPOAb positivity during pregnancy with child IQ in two large, prospective, 85	
population-based cohorts. 86	
Methods 87	
This study was embedded in two prospective birth cohorts: Generation R (Rotterdam, the 88	
Netherlands) and the Avon Longitudinal Study of Parents and Children (ALSPAC), United 89	
Kingdom).  90	
Study design and participants 91	
In Generation R, 7069 women with a delivery date between April 2002 and January 2006 were 92	
enrolled during early pregnancy (≤18 weeks) in hospitals and midwife practices in the Rotterdam area 93	
(33). Blood samples were drawn in 6398 of these women and 5793 had enough material for 94	
measurement of TPOAbs. When the children reached 5 years of age, all enrolled mothers and children 95	
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were invited to visit the research center at the Erasmus MC Sophia Children’s Hospital in Rotterdam, 96	
where 3753 (64%) children underwent IQ assessments. The general study design, all research aims, 97	
and the specific measurements in the Generation R Study have been approved by the Medical Ethical 98	
Committee of the Erasmus Medical Center, Rotterdam, Netherlands. Written informed consent was 99	
obtained from all participants and/or the children’s parents or guardians. 100	
In ALSPAC, eligible women were those living in the former Avon area in southwest England, United 101	
Kingdom, with an expected delivery date between April, 1991, and December, 1992. In total, blood 102	
samples were available in 7501 pregnant women, of which 4947 were enrolled during early pregnancy 103	
(≤18 weeks) (34) with 4916 women having TPOAb measurements. Subsequently, all participants 104	
were invited to attend a research clinic where trained psychologists measured the IQ of 2552 children.  105	
The study website contains details of all the data that are available through a fully searchable database 106	
www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/. Ethical approval for the study was 107	
obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. 108	
Laboratory Measurements 109	
In Generation R, maternal blood samples collected in early pregnancy were stored at -80° C. Maternal 110	
TPOAbs were measured using the Phadia 250 immunoassay (Phadia AB, Uppsala, Sweden) and 111	
considered positive when the serum concentrations were >60 IU/ml. FT4 and TSH were measured 112	
using chemiluminescence assays (Vitros ECI Immunodiagnostic System Ortho Clinical Diagnostics, 113	
Rochester, NY). The intra- and interassay coefficients of variation were <4.1% for TSH at a range of 114	
3.97–22.7 mU/L and <5.4% for FT4 at a range of 14.3–25.0 pmol/L. Details of the urinary iodine and 115	
creatinine measurement are reported elsewhere (35).  116	
In ALSPAC, TPOAb, FT4 and TSH were measured in stored serum samples using an Abbott 117	
Architect i2000. Inter- and intra-assay coefficients of variation were less than 5% for all analytes. 118	
TPOAbs were considered positive when the serum concentrations were ≥6 IU/ml. Details on urinary 119	
iodine and creatinine measurements are reported elsewhere (36). 120	
121	
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Outcomes 122	
In Generation R, non-verbal child IQ was evaluated using two subtests of a Dutch non-verbal 123	
intelligence test, the Snijders-Oomen Niet-Verbale Intelligentie Test when the children were 5 to 8 124	
years of age. The test generally evaluates a range of intelligence functions without relying on 125	
language skills and is therefore suitable for assessing the cognitive abilities of ethnic minorities’ 126	
children and children with verbal communication problems (37). The two subtests were mosaics 127	
(evaluating spatial visualization abilities) and categories (evaluating abstract reasoning abilities) and 128	
the correlation between subtests with complete test were: r=0.86. Raw test scores were converted into 129	
non-verbal IQ scores using normal values tailored to exact age. Research staff who did the IQ tests 130	
were unaware of any other mother-child measurements and outcomes.  131	
In ALSPAC, child IQ was measured in a research clinic using a well-validated age-adjusted shortened 132	
form of the Wechsler Intelligence Scale for Children (WISC) which provides a well-standardized 133	
assessment of performance and verbal intelligence when children were 7 to 10 years of age (36,38). 134	
WISC assessments were administered by trained psychologists. To compare analyses to Generation R, 135	
the performance component of child IQ was used as the primary outcome, supplementary analyses 136	
were also performed for the verbal component. 137	
Statistical analysis 138	
We used multivariable linear regression analyses to investigate the association of maternal TPOAb 139	
positivity with child IQ. We have recently shown that thyroid function and the response to hCG 140	
stimulation is already lower from concentrations below currently used TPOAb positivity cut-offs as 141	
provided by assay manufacturers (39). Therefore, we also performed sensitivity analyses to evaluate 142	
the effects of cut-offs below the currently used manufacturer-based cut-offs. TPOAbs were 143	
categorized at 20, 30, 40, 50 and 60 IU/ml in Generation R (corresponding to population-based 144	
percentiles: 90.6, 92.2, 93, 93.6 and 94.1, respectively). To enable comparison between cohorts, 145	
population-based cut-offs equivalent to the cut-offs in Generation R were defined in ALSPAC (14.2, 146	
29.6, 41.4, 54.8 and 63.1 IU/ml, respectively). The effect estimates for these cut-offs were compared 147	
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with TPOAb <10 IU/ml (population-based percentile of 83) in Generation R and the corresponding 148	
percentile (<4.16 IU/ml) in ALSPAC. The severely skewed distribution of (log-transformed) TPOAb 149	
concentrations did not allow for reliable analyses using TPOAb concentrations as a continuous 150	
exposure. Outliers of IQ were defined and excluded based on ±2.5*(median absolute deviation). 151	
Based on the current ATA guidelines (4), we additionally investigated the group of TPOAb positive 152	
women with a TSH concentration >2.5 mU/L (N=118 (3.4 %) and N=52 (2.46 %), in Generation R 153	
and ALSPAC, respectively). Because maternal iodine status is a well-known determinant of both 154	
thyroid autoimmunity and child IQ (3,36), in a subset of mothers with available early pregnancy 155	
iodine data (N=753 in Generation R and N=1065 in ALSPAC) we investigated the possible effects of 156	
maternal iodine status on the association of TPOAbs with child IQ by: 1) studying the association of 157	
TPOAbs with maternal urinary iodine/creatinine ratio (UICr) using a linear regression model; 2) 158	
additionally adjusting all analyses for maternal UICr; and 3) stratify analyses in both cohorts 159	
according to a UICr below and above 150 µg/g. Furthermore, we also investigated if the association 160	
of maternal TPOAbs with child IQ would be (partially) mediated via changes in maternal thyroid 161	
function by additionally adjusting all models for maternal FT4. 162	
All analyses were adjusted for maternal age, body mass index, parity, smoking status, education level, 163	
ethnicity, gestational age at the time of blood sampling, child sex and birth weight. We used multiple 164	
imputation by chained equations to deal with missing data of covariates (40). The maximum 165	
percentage of missing data was 10.3% in Generation R and 3.7% for ALSPAC. The number of 166	
imputations were based on the percentage of missing data using at least 1 imputation per percent of 167	
incomplete cases (41). All statistical analyses were performed using Statistical Package of Social 168	
Sciences version 21.0 for Windows (SPSS, Chicago, IL) or R statistical software version 3.3.2 169	
(packages mice and rms; https://www.r-project.org/).  170	
Results 171	
After exclusions, the final study population comprised 6033 mother-child pairs (Generation R: 172	
N=3637; ALSPAC: N=2396, Figure 1). Mother-child characteristics of the study population are 173	
shown in Table 1. In Generation R, the prevalence of TPOAb positivity was 5.9%, the mean 174	
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gestational age at blood sampling was 13.4 (SD 1.9) weeks and the study population was mainly of 175	
Dutch ethnicity (57.3%). In ALSPAC, the prevalence of TPOAb positivity was 12.8%, the mean 176	
gestational age at blood sampling was 10.9 (SD 3.1) weeks and the study population was mainly of 177	
Caucasian ethnicity (98.5%). In both cohorts, there was no difference in maternal TPOAb positivity or 178	
thyroid function between mother-child pairs with or without IQ data available (Supplemental Tables 1 179	
and 2). 180	
In Generation R, maternal TPOAb positivity was associated with lower mean child IQ (-2.0 ±0.9 181	
points, P=0.03; Table 2). Subsequent sensitivity analyses showed that mean child IQ was already  182	
lower at TPOAb cut-offs below the currently used manufacturer-based cut-off for TPOAb positivity 183	
(Table 2). In ALSPAC, neither TPOAb positivity nor TPOAb cut-offs below the manufacturer-based 184	
cut-off were associated with child IQ (TPOAb positivity: 0.7 ±1.0 points; P=0.45; Table 2). The 185	
combination of TPOAb positivity with a TSH above 2.5 mU/l was not associated with child IQ in 186	
Generation R (P for interaction=0.52) while this combination was associated with a higher mean child 187	
IQ in ALSPAC (P for interaction=0.09; Supplemental Table 3). All results remained essentially 188	
unchanged after adjusting for maternal FT4 concentrations (Table 2), UICr (Supplemental Table 4) or 189	
hCG concentrations (Generation R only; data not shown). 190	
The median maternal UICr differed considerably between Generation R and ALSPAC (median (IQR): 191	
277 (194-383) vs. 117 (80-190), P<0.001). In ALSPAC, but not in Generation R, higher TPOAb 192	
concentrations or TPOAb positivity were associated with higher maternal UICr, although these 193	
analyses did not reach statistical significance in the smaller subgroups (Supplemental Table 5). 194	
Sensitivity analyses indicated that the association of maternal TPOAb positivity with child IQ may 195	
differ according to maternal iodine status, although we lacked adequate statistical power for this 196	
analysis (Supplemental Table 6).  197	
Discussion 198	
In this study, we investigated the association of TPOAb positivity during early pregnancy with child 199	
IQ in two large prospective population-based cohorts. We show that TPOAb positivity as defined by 200	
currently used manufacturer-based cut-offs was associated with lower mean child IQ in the 201	
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Netherlands (Generation R) but not in the United Kingdom (ALSPAC). Furthermore, the association 202	
of TPOAbs with lower child IQ in the Netherlands was already present from TPOAb cut-offs below 203	
the currently used manufacturer-based cut-offs. Additional adjustment for maternal FT4 204	
concentrations or UICr did not change the results but sensitivity analyses indicated a potential role for 205	
iodine status as an effect modifier. 206	
The peak activity of fetal brain development overlaps with the period during which the fetus is 207	
dependent on the placental transfer of maternal thyroid hormones (8,11,13). However, TPOAb 208	
positive women have an impaired response to the thyroidal stimulation by hCG and low maternal 209	
thyroid hormone availability is associated with lower child IQ (42-45). In the current study, TPOAb 210	
positivity was associated with lower child IQ in Generation R. We speculate that the lower IQ in 211	
children of TPOAb positive mother could be a reflection of the lack of hCG mediated increase in FT4 212	
concentrations during early pregnancy. Alternatively, TPOAb positivity could be associated with 213	
lower child IQ because it reflects a higher general susceptibility to autoimmunity. Thyroid 214	
autoimmunity is associated with higher T helper cytokines and an increased natural killer cell activity 215	
(46) and maternal autoimmunity or a familial history of autoimmune disorders has been associated 216	
with a higher risk of child autism (47,48). Another possible explanation could be a direct effect of 217	
TPOAbs on the brain. TPOAbs can cross the placenta and have been detected in the cerebrospinal 218	
fluid of patients with Hashimoto’s encephalitis, possibly contributing to the pathogenesis of the 219	
disease by binding to cerebellar astrocytes or causing vasculitis (49,50). 220	
Although TPOAb positivity was associated with a lower child IQ in Generation R, there was no 221	
association in ALSPAC, for which point estimates even suggested that TPOAb positivity is associated 222	
with a higher child IQ. The discrepancy between the two cohorts could be caused via different 223	
mechanisms. First of all, there is a large difference in iodine status of pregnant women between the 224	
Netherlands (more than sufficient) and United Kingdom (mild deficient), as was also reflected by the 225	
UICr analyses in the current study. Both low and high iodine intake are a risk factor for low maternal 226	
thyroid hormone availability and also increase the risk of thyroid autoimmunity (3,51). Previous 227	
studies show that low maternal UICr is not associated with child IQ in Generation R, while in 228	
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ALSPAC low UICr is associated with lower child IQ (36,52). In this study, higher TPOAb 229	
concentrations and TPOAb positivity were associated with higher maternal UICr in ALSPAC, 230	
although the size of the subset with available data did not allow these analyses to reach statistical 231	
significance. Taken together, this suggests that the difference between Generation R and ALSPAC, 232	
and also the positive point estimates in ALSPAC, could be due to the fact that TPOAbs coincide with 233	
a higher iodine concentrations in ALSPAC. Unfortunately, data on UICr was only available in a small 234	
subset for both studies, precluding adequate analyses to investigate the role of UICr as an underlying 235	
cause for the differences between the two cohorts. However, stratified analysis did show that in 236	
Generation R, the association of TPOAb positivity with lower child IQ was driven predominantly by 237	
women with a UICr  ≥150 µg/g. This indicates that in Generation R, low iodine status is not the 238	
underlying mechanism. In addition, in studies from iodine sufficient populations, TPOAb positivity 239	
has been associated with impaired child cognition, autism and behavioral problems (27,30,31) 240	
whereas a Scottish study with 40% of women being iodine deficient did not find an association with 241	
neurodevelopmental outcomes (29).  242	
Second, while in Generation R serum samples were collected between 2002 and 2005 and TPOAbs 243	
were measured in 2006, ALSPAC samples were collected between 1991 and 1992 and measured in 244	
2016. A study from Finland shows that in stored serum samples, there is a strong positive association 245	
of storage time with TPOAb concentrations, with storage time explaining 19.7% of the total variation 246	
in TPOAb concentrations (53). This indicates that TPOAb concentrations in ALSPAC are much more 247	
likely to be subject to measurement error than those in Generation R. Although it is unknown whether 248	
the extent of the increase in TPOAb concentration by storage time is differential on factors that may 249	
affect IQ, the difference in storage time may hamper the comparisons between Generation R and 250	
ALSPAC in the current study. 251	
The current ATA guidelines recommend that treatment can be considered in TPOAb positive women 252	
if the TSH concentration is >2.5 mU/l (18), however, no recommendations are currently provided for 253	
the definition of TPOAb positivity. In the current study, the association of TPOAb positivity with 254	
lower child IQ in Generation R did not differ according to a TSH below or above 2.5 mU/l. 255	
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Furthermore, two recent studies identified that any potential beneficial effects of levothyroxine 256	
treatment in TPOAb positive women or women with subclinical hypothyroidism, only occurs in 257	
women with a TSH above 2.5 mU/l (namely 4.0 mU/l) (20,21). Therefore, further studies are required 258	
to investigate from which TSH threshold the risk of adverse outcomes in TPOAb positive women 259	
starts to increase. In addition, a previous study from our group showed that TPOAb concentrations 260	
already below currently used manufacturer cut-offs are associated with a higher TSH and a higher risk 261	
of premature delivery (39). In the current study, we also showed that TPOAb cut-offs below the 262	
currently used manufacturer-based cut-offs for TPOAb positivity were associated with a lower child 263	
IQ. Taken together, this suggests that the clinically relevant cut-off for TPOAb positivity may differ 264	
from the currently used manufacturer-based cut-offs and that future studies should focus on 265	
identifying the optimal threshold for TPOAb positivity. 266	
To the best of our knowledge, this is the first study to assess the association of early pregnancy 267	
TPOAb positivity with child IQ in two large prospective, population-based cohorts. We were able to 268	
study this association in two study populations with a different population iodine status with detailed 269	
data that allowed us to adjust the models for important confounders and run additional sensitivity 270	
analyses. 271	
A potential limitation of this study is that data on maternal iodine status was not available for all 272	
mothers which left us with inadequate statistical power for sensitivity analysis investigating the 273	
potential role of iodine intake. Further studies are needed to investigate the role of maternal iodine 274	
status in the association of thyroid autoimmunity with child cognitive development. In addition, the 275	
number of TPOAb positive women with a TSH >2.5 mU/l was small, hampering an adequately 276	
powered analyses for this group.  277	
In conclusion, we demonstrate that TPOAb positivity during early pregnancy is associated with lower 278	
child IQ in a Dutch, iodine sufficient population, but not in a mildly iodine deficient population from 279	
the United Kingdom. In addition, TPOAb cut-offs below the current manufacturer-based cut-offs 280	
were associated with lower mean child IQ in the Netherlands. Further studies are needed to 281	
investigate the association of TPOAbs with child neurodevelopment outcomes in different 282	
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populations, and evaluate whether factors that affect thyroid autoimmunity, such as iodine status, 283	
might possibly modify this association.   284	
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